文献速递艾滋病与性传播感染病毒性肝炎

当代HIV与丙型肝炎病毒治疗时代增强型肝纤维化评分的纵向评估

Longitudinal Assessment of the Enhanced Liver Fibrosis Score in the Era of Contemporary HIV and Hepatitis C Virus Treatment.
PubMed 文献 · J Infect Dis · 2023-01-01

在116例HIV/HCV合并感染女性中,4年内评估ELF、APRI和FIB-4。未调整分析显示HCV治疗前ELF上升速率为3.3%,围HCV治疗期和HCV治疗后1年分别下降2.2%和3.6%,之后上升0.3%。调整年龄、种族及可能影响纤维化因素的变化后,纤维化轨迹估计影响很小。

要点

  • HCV治疗前ELF上升速率为3.3%,围治疗期和治后1年分别下降2.2%和3.6%。
  • HCV治愈1年后肝纤维化生物标志物未见明显下降。
  • HIV患者HCV治愈后仍需继续监测肝纤维化并干预以减缓进展。

核心结论

  • HCV治愈1年后肝纤维化生物标志物未见明显下降,提示HIV患者HCV治愈后继续监测肝纤维化和干预以减缓进展仍至关重要。

研究设计与样本

  • 纵向评估116例HIV/HCV合并感染女性4年内ELF、APRI和FIB-4的变化。
  • 采用随机效应线性回归模型分析HCV治疗前1-2年、围HCV治疗期(治疗前1年内)、治疗后1年内及治疗后1-2年的纤维化变化速率,包括未调整和调整年龄、种族及可能影响纤维化因素(如酒精、INSTI使用、腰围、CD4计数)从治疗前变化的模型。

主要发现

  • INSTI使用从HCV治疗前到围HCV治疗期几乎翻倍。
  • 未调整分析中,ELF在HCV治疗前上升速率为3.3%,围HCV治疗期和HCV治疗后1年分别下降2.2%和3.6%,之后上升0.3%。
  • APRI和FIB-4观察到相似结果。
  • 调整后对估计的纤维化轨迹影响很小。

临床怎么用

  • 作者认为,HIV患者HCV治愈后继续监测肝纤维化和干预以减缓进展仍至关重要。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The trajectory of liver fibrosis is not well understood in the contemporary era of human immunodeficiency virus (HIV) and hepatitis C virus (HCV) therapy. METHODS: We assessed the Enhanced Liver Fibrosis (ELF) score, aspartate transaminase-to-platelet ratio index (APRI) and Fibrosis-4 (FIB-4) in 116 women with HIV/HCV coinfection over a 4-year period. Random-effects linear regression models examined the rate of fibrosis change 1-2 years before starting HCV treatment, within 1 year before starting (peri-HCV treatment), within 1 year after and 1-2 years post-HCV treatment in unadjusted and adjusted models including age, race, and changes from pretreatment of factors that might affect fibrosis (eg, alcohol, integrase strand inhibitor [INSTI] use, waist circumference, CD4 count). RESULTS: INSTI use nearly doubled from pre- to peri-HCV treatment. In unadjusted analysis, there was a 3.3% rate of rise in ELF pre-HCV treatment, 2.2% and 3.6% rate of decline during the peri- and 1-year post-HCV treatment period, respectively, followed by a 0.3% rise. Similar findings were observed for APRI and FIB-4. There was little effect on the estimated fibrosis trajectories after adjustment. CONCLUSIONS: The apparent lack of decline in biomarkers of liver fibrosis beyond 1 year after HCV cure suggests that continued monitoring of liver fibrosis and interventions to mitigate progression in people with HIV after HCV cure remains essential.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Gardner AR, Ma Y, Bacchetti P, et al. Longitudinal Assessment of the Enhanced Liver Fibrosis Score in the Era of Contemporary HIV and Hepatitis C Virus Treatment. J Infect Dis. 2023. PMID: 35951669. doi:10.1093/infdis/jiac315

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。